ENVIRONMENTAL ANTI-ANDROGENS AND AR AUTOREGULATION

环境抗雄激素和 AR 自动调节

基本信息

项目摘要

Androgen receptors (ARs) play an important role in regulating the expression of genes necessary for normal development of the male urogenital tract and for the maintenance of reproductive function. AR functions as a ligand-activated transcription factor and has been implicated in a number of human pathologies, most notably prostate cancer. AR also undergoes autoregulation, a process by which androgens regulate AR mRNA transcription and AR protein stability. This action may be a mechanism by which cells can alter their responsiveness to androgens. My sponsor and others have shown that AR mRNA levels may correlate with androgen sensitivity. Industrial chemicals and the so-called "environmental endocrine disruptors" may interfere with androgen-mediated activities. The increasing incidence of human male genital tract malformations, male infertility, and female breast cancer may be due in part to antiandrogenic effects of these compounds. Studies suggest that two such chemicals, DDE (a metabolite of the pesticide DDT) and M2 (a metabolite of the fungicide vinclozolin) inhibit AR DNA-binding and the subsequent transactivation of target genes. Also, other laboratories have found that these chemicals may possess agonist activities, especially at high concentrations. This proposal seeks to assess the effects of DDE and M2 on AR autoregulation as well as the effects of pre-exposure to these chemicals on cellular responsiveness to androgen. Two different models of androgen target tissues, LNCap (prostate cancer) and T47D (breast cancer), will be used for these studies. Our long- term goal is to elucidate the mechanisms by which these environmental antiandrogens affect AR autoregulation and responsiveness and how these effects may be associated with detrimental and developmental pathologies.
雄激素受体(AR)在调节男性泌尿生殖道正常发育和维持生殖功能所必需的基因表达方面起着重要作用。AR作为一种配体激活的转录因子发挥作用,并与许多人类病理有关,最明显的是前列腺癌。AR也经历自我调节,这是雄激素调节AR mRNA转录和AR蛋白稳定性的过程。这种作用可能是细胞改变其对雄激素反应的一种机制。我的赞助人和其他人已经证明,AR mRNA水平可能与雄激素敏感性有关。工业化学品和所谓的“环境内分泌干扰物”可能会干扰雄激素介导的活动。人类男性生殖道畸形、男性不育症和女性乳腺癌发病率的增加可能部分是由于这些化合物的抗雄激素作用。研究表明,两种这样的化学物质,DDE(杀虫剂DDT的代谢物)和M2(杀菌剂长春新灵的代谢物)抑制AR DNA结合和随后的靶基因反式激活。此外,其他实验室也发现,这些化学物质可能具有激动剂活性,特别是在高浓度下。这项建议旨在评估DDE和M2对AR自身调节的影响,以及预先暴露于这些化学物质对细胞对雄激素的反应的影响。两种不同的雄激素靶向组织模型LNCaP(前列腺癌)和T47D(乳腺癌)将用于这些研究。我们的长期目标是阐明这些环境抗雄激素影响AR自身调节和反应性的机制,以及这些影响可能如何与有害和发育病理相关联。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Eddy Shih-Hsin Yang其他文献

Gene Expression Profiling of Advanced Penile Squamous Cell Carcinoma Receiving Cisplatin-based Chemotherapy Improves Prognostication and Identifies Potential Therapeutic Targets
  • DOI:
    10.1016/j.euf.2016.08.001
  • 发表时间:
    2018-09-01
  • 期刊:
  • 影响因子:
  • 作者:
    Andrea Necchi;Bernhard J. Eigl;Eddy Shih-Hsin Yang;Sejong Bae;Darshan Chandrashekar;Dongquan Chen;Gurudatta Naik;Amitkumar Mehta;Patrizia Giannatempo;Maurizio Colecchia;Jennifer Gordetsky;Shi Wei;Tiffiny Cooper;Sooryanarayana Varambally;Guru Sonpavde
  • 通讯作者:
    Guru Sonpavde

Eddy Shih-Hsin Yang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Eddy Shih-Hsin Yang', 18)}}的其他基金

MULTICENTER TRIAL OF FETAL MYELOMINEINGOCELE REPAIR
胎儿骨髓膨出修复的多中心试验
  • 批准号:
    7605570
  • 财政年份:
    2006
  • 资助金额:
    $ 2.09万
  • 项目类别:
MULTICENTER TRIAL OF FETAL MYELOMINEINGOCELE REPAIR
胎儿骨髓膨出修复的多中心试验
  • 批准号:
    7731395
  • 财政年份:
    2006
  • 资助金额:
    $ 2.09万
  • 项目类别:
ENVIRONMENTAL ANTI-ANDROGENS AND AR AUTOREGULATION
环境抗雄激素和 AR 自动调节
  • 批准号:
    6730648
  • 财政年份:
    2002
  • 资助金额:
    $ 2.09万
  • 项目类别:
ENVIRONMENTAL ANTI-ANDROGENS AND AR AUTOREGULATION
环境抗雄激素和 AR 自动调节
  • 批准号:
    6877028
  • 财政年份:
    2002
  • 资助金额:
    $ 2.09万
  • 项目类别:
ENVIRONMENTAL ANTI-ANDROGENS AND AR AUTOREGULATION
环境抗雄激素和 AR 自动调节
  • 批准号:
    6635452
  • 财政年份:
    2002
  • 资助金额:
    $ 2.09万
  • 项目类别:
ENVIRONMENTAL ANTI-ANDROGENS AND AR AUTOREGULATION
环境抗雄激素和 AR 自动调节
  • 批准号:
    6382115
  • 财政年份:
    2001
  • 资助金额:
    $ 2.09万
  • 项目类别:
ENVIRONMENTAL ANTI-ANDROGENS AND AR AUTOREGULATION
环境抗雄激素和 AR 自动调节
  • 批准号:
    6139960
  • 财政年份:
    2000
  • 资助金额:
    $ 2.09万
  • 项目类别:
02 - Experimental Therapeutics
02 - 实验疗法
  • 批准号:
    10629235
  • 财政年份:
    1997
  • 资助金额:
    $ 2.09万
  • 项目类别:
03 Experimental Therapeutics Program
03 实验治疗计划
  • 批准号:
    10362797
  • 财政年份:
    1997
  • 资助金额:
    $ 2.09万
  • 项目类别:
02 - Experimental Therapeutics
02 - 实验疗法
  • 批准号:
    10411028
  • 财政年份:
    1997
  • 资助金额:
    $ 2.09万
  • 项目类别:

相似海外基金

Androgen receptor: A master regulator of lipid metabolism
雄激素受体:脂质代谢的主要调节因子
  • 批准号:
    DP230103210
  • 财政年份:
    2023
  • 资助金额:
    $ 2.09万
  • 项目类别:
    Discovery Projects
Regulation of androgen receptor signaling in prostate cancer by protein arginine methylation
通过蛋白质精氨酸甲基化调节前列腺癌中的雄激素受体信号传导
  • 批准号:
    10584689
  • 财政年份:
    2023
  • 资助金额:
    $ 2.09万
  • 项目类别:
Structural and functional analysis of a novel class of androgen receptor antagonists
一类新型雄激素受体拮抗剂的结构和功能分析
  • 批准号:
    10650956
  • 财政年份:
    2023
  • 资助金额:
    $ 2.09万
  • 项目类别:
Role of the Androgen Receptor in Insulin Secretion in the Male
雄激素受体在男性胰岛素分泌中的作用
  • 批准号:
    10488954
  • 财政年份:
    2023
  • 资助金额:
    $ 2.09万
  • 项目类别:
Targeting tumor cell macrophage lipid interactions to overcome resistance to androgen receptor targeted therapy
靶向肿瘤细胞巨噬细胞脂质相互作用以克服对雄激素受体靶向治疗的耐药性
  • 批准号:
    10651105
  • 财政年份:
    2023
  • 资助金额:
    $ 2.09万
  • 项目类别:
Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease
ONCT-505(一种雄激素受体拮抗剂和降解剂)的临床前开发,作为肯尼迪病的新潜在治疗方法
  • 批准号:
    10603636
  • 财政年份:
    2023
  • 资助金额:
    $ 2.09万
  • 项目类别:
Androgen receptor function in melanoma
雄激素受体在黑色素瘤中的功能
  • 批准号:
    10416658
  • 财政年份:
    2022
  • 资助金额:
    $ 2.09万
  • 项目类别:
Proliferating cell nuclear antigen in regulation of androgen receptor signalings in castration-resistant prostate cancer cells
增殖细胞核抗原对去势抵抗性前列腺癌细胞雄激素受体信号传导的调节
  • 批准号:
    10544062
  • 财政年份:
    2022
  • 资助金额:
    $ 2.09万
  • 项目类别:
Effects of androgen receptor (AR) signaling on CD4+ T cell metabolism during airway inflammation
气道炎症期间雄激素受体 (AR) 信号对 CD4 T 细胞代谢的影响
  • 批准号:
    10534943
  • 财政年份:
    2022
  • 资助金额:
    $ 2.09万
  • 项目类别:
TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDE
标题:使用雄激素受体抑制剂阿帕鲁胺进行膀胱癌化学预防
  • 批准号:
    10677989
  • 财政年份:
    2022
  • 资助金额:
    $ 2.09万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了